And the link between Sam Altman and Retro BioSciences is not reduced to finances alone. Because the start-up benefited from OpenAi’s expertise to develop a tailor-made AI model, which allows you to develop very special proteins. These are indeed capable of temporarily transforming normal cells into stem cells. A method that would reverse the aging process.
Retro Biosciences wants this year to launch a clinical trial this year, the objective of which is to find a treatment for Alzheimer’s disease. The start-up also wants to develop treatments to rejuvenate blood and brain cells. Potential advances which, if they became effective, could simply make it possible to considerably increase the duration of human life. A dream has long been present in Silicon Valley.
Using AI, Retro Biosciences also hopes to be able to advance much faster than usual in the development of treatments. “” The line we are dealing with in the sand is, damn it that our first drug will be put on the market in the 2020s »Enthuses the boss, Joe Betts-Lacroix. So, fantasy, or future reality?
Tech
